Papers from every journal, all in one place. Launch research agents to watch your topics.
While very interesting that 91% had positive CVB serologies, prevalence is probably not the best term to use, as to be included in the analysis, patients had to have sarcoidosis and available CVB testing. Prevalence could be defined if all sarcoidosis patients had CVB testing.
Open HeartDonnelly et al.
Yoga-based cardiac rehabilitation (Yoga-CaRe) is an innovative multicomponent cardiac rehabilitation with yoga to address the unmet needs of cardiac rehabilitation in India and in other resource-constrained settings. Yoga-CaRe HF evaluates whether Yoga-CaRe improves cardiovascular health in a multicenter randomized trial involving near 3500 patients with heart failure with reduced ejection fraction. Results will be presented at the AHA on Nov 7, 2026 as a late-breaking science.
Balasubramaniam et al.
Interventional Cardiologist · Charles University and University Hospital Kralovske Vinohrady
Using the blueprint already employed for heart attacks, we were able to demonstrate that specialised interventional treatment can be delivered in tertiary care centres across our national network. This may pave the way for an improved, standardised approach to the treatment of pulmonary embolism, reducing the acute risks that patients face.
New England Journal of MedicineKroupa et al.
Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.
New England Journal of MedicineHausleiter et al.
BHF Professor of Cardiology, University of Edinburgh · University of Edinburgh
Our findings provide strong evidence that patients who have had a heart attack excluded do not benefit from early outpatient CTCA scans. Once we are confident that they haven't had a heart attack, we can reassure these patients that their future risk is low and send them home.
New England Journal of MedicineLee et al.
Lead Researcher · Monash University School of Public Health and Preventive Medicine
A notable finding is that the lower incidence of major, nonfatal cardiovascular events with atorvastatin than with placebo did not result in a corresponding improvement in disability-frees survival. Explanations for this result might include the fact that 80% of the deaths in the trial were from non-cardiovascular causes.
New England Journal of MedicineZoungas et al.
The key impact on clinical practice is that the level of evidence about this population was actually very low, and this is the first [randomized controlled trial] to support that DOAC therapy can give benefit to this patient population.
New England Journal of MedicineKim et al.
Cardiologist · Copenhagen University Hospital
It seems that from POET I and POET II we have challenged dogmas showing that less intensive antibiotic therapy after stabilization is superior and safe. And we think that defining the stabilization point is a kind of personalizing endocarditis treatment.
New England Journal of MedicineBundgaard et al.
Cardiologist · Nanjing First Hospital
Despite major advances in pharmacologic and device-based therapies, pulmonary hypertension remains one of the strongest predictors of hospitalization, right ventricular failure, and death in patients with left heart disease and heart failure. … Additional long-term follow-up will be important to determine whether the observed mid-term improvements translate into sustained reductions in mortality and hospitalization for HF.
New England Journal of MedicineZhang et al.
Expert commentary · @gbiondizoccai
In the 986-patient TAVI PCI RCT, a strategy of TAVI before PCI yielded similar outcome to a strategy of PCI before TAVI at 1 year in patients with both aortic stenosis and CAD (25% MVD) https://t.co/8d0elI9CeM #CAD #PCI #TAVI #TAVR @NEJM @escardio https://t.co/OEZFeSNXLq
New England Journal of MedicineStähli et al.
Cardiologist · Oregon Health & Science University
Results from the ACACIA-HCM trial provide really positive news for patients with symptomatic non-obstructive HCM. For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.
New England Journal of MedicineMasri et al.
Professor of Clinical and Interventional Cardiology · Leipzig University
Our data show that most of the improvement reported by patients does not appear to be attributable to catheter ablation itself, but rather to factors such as a placebo effect or adjustments to their medication. Current guidelines recommend catheter ablation primarily to prevent the recurrence of atrial fibrillation and improve quality of life. However, our study shows that the effect of the ablation itself does not adequately explain the improvement in quality of life.
The LancetWachter et al.
